The information contained in this website has been developed by Arcutis Medical Affairs and is intended for US healthcare professionals (HCPs) only.
Explore a collection of congress presentations and published literature from Arcutis.
Correlation of Itch Response to Roflumilast Cream with Disease Severity and Patient-Reported Outcomes in Patients with Chronic Plaque Psoriasis
Effect of Roflumilast Cream on Chronic Plaque Psoriasis in Patients with Steroid-Sensitive Area Involvement
Once-Daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-Blind, Vehicle-Controlled Phase 2b Study
The PASI-HD for Precision in Measuring Disease Severity in Subjects with Mild to Moderate Plaque Psoriasis Treated with Roflumilast Cream, a Phosphodiesterase-4 Inhibitor
The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Efficacy and Safety of Once-Daily Roflumilast Cream 0.3% in Patients with Psoriasis (DERMIS-1 and DERMIS-2)
Roflumilast Cream 0.3% for the Severity and Impact of Itch in Patients with Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies
Roflumilast Cream, a Once-Daily, Potent Phosphodiesterase-4 Inhibitor, in Chronic Plaque Psoriasis Patients: Efficacy and Safety from DERMIS-1 and DERMIS-2 Phase 3 Trials
Long-Term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients with Chronic Plaque Psoriasis: Results from a 52-Week, Phase 2b Open-Label Study
Assessment of the Vehicle for Roflumilast Cream Compared to a Commercially Marketed, Ceramide-Containing Moisturizing Cream in Patients with Mild Eczema
Your file will open automatically upon submission.
Fields marked with an asterisk (*) are required.
Arcutis Biotherapeutics, Inc. (“Arcutis”) understands that protecting your personal information is very important. We do not share any personally identifiable information you give us with third parties for their own marketing purposes.
I would like to receive occasional information from Arcutis about products, services, and opportunities that may be of interest to me and agree to allow Arcutis to use the information provided for this purpose. Examples include, but are not limited to, information or opportunities to participate in surveys or provide feedback, and information about clinical trials.
I can opt out at any time by clicking “Unsubscribe” at the bottom of any such communication, calling 805-418-5006, or by sending a letter to Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
For additional details, please see Arcutis’ Privacy Policy.
By clicking Download below, I am agreeing to receive the requested information. I further acknowledge the Arcutis Privacy Policy and affirm that I am at least eighteen (18) years of age.
Δ
You are now leaving the Arcutis Medical Affairs website. Arcutis Biotherapeutics is not responsible for the content on these third-party websites.